Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

NCT02022098 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT02022098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02022098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Lead sponsor
Debiopharm International SA
Phase
Not applicable
Overall status
Completed
Start date
October 31, 2013
Completion date
April 28, 2022
Enrollment
144 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck